Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 7141 AL 7155

Active immunization: A novel therapeutic strategy for treating Alzheimer's disease

Mazahir F.

Eur J Pharmacol. 2025 Nov 15;1007:178288. doi: 10.1016/j.ejphar.2025.178288. Epub 2025 Oct 24.

Alzheimer Combination Therapies: Overview and Scenarios

Cummings JL, Burstein AH, Fillit H.

J Prev Alzheimers Dis. 2025 Dec;12(10):100328. doi: 10.1016/j.tjpad.2025.100328. Epub 2025 Oct 27.

Add-on combination therapy with monoclonal antibodies: Implications for drug development

Cummings J, Burstein AH, Fillit H.

J Prev Alzheimers Dis. 2025 Dec;12(10):100359. doi: 10.1016/j.tjpad.2025.100359. Epub 2025 Oct 27.

Peripheral immune and metabolic regulation of Aβ and Tau by exercise in Alzheimer's disease

Yu Y, Chen K.

Front Immunol. 2025 Oct 15;16:1678526. doi: 10.3389/fimmu.2025.1678526. eCollection 2025.

Targeting the C5-C5aR1 axis: A promising therapeutic strategy for Alzheimer's disease and amyotrophic lateral sclerosis by unlocking neuroprotection

Ge TQ, Wang P, Guan PP.

Biochem Pharmacol. 2026 Jan;243(Pt 1):117518. doi: 10.1016/j.bcp.2025.117518. Epub 2025 Nov 2.

Tau Liquid-Liquid Phase Separation in Alzheimer's Disease: Mechanisms, Pathogenesis, and Therapeutic Implications

Tian S, Liu Y, Hu H, Li S.

Mol Neurobiol. 2025 Nov 9;63(1):18. doi: 10.1007/s12035-025-05280-y.

APOE-Targeted Therapeutics for Alzheimer's Disease

Yassine HN, Hugo C, O'Donovan B, Stephens IO, Johnson LA, Cole G, Tcw J, Johansson J, Kisler K, Chiba-Falek O.

J Neurosci. 2025 Nov 12;45(46):e1388252025. doi: 10.1523/JNEUROSCI.1388-25.2025.

Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer's disease

Sharma A, Singh TG.

Brain Res. 2026 Jan 1;1870:150047. doi: 10.1016/j.brainres.2025.150047. Epub 2025 Nov 13.

Breaking the Alzheimer's Treatment Stalemate: Synergistic Application Strategies of Nanomaterials and Pharmaceutical Agents

Gao H, Cheng F, Zhang Z, Yan B, Liao P, Zhang S, Li D, Chen F, Lei P.

Mol Neurobiol. 2025 Nov 20;63(1):107. doi: 10.1007/s12035-025-05320-7.

Recent development in PDE4D-targeted inhibitors for Alzheimer's disease therapy

Sun T, Li Z, Xiao B, Yang J, Han M, Zhang J, Liu S, Ma J, Sang Z, Wang P.

Eur J Med Chem. 2026 Jan 15;302(Pt 3):118383. doi: 10.1016/j.ejmech.2025.118383. Epub 2025 Nov 17.

From genes to lifestyle: A multi-dimensional framework for Alzheimer's disease prevention and therapy

Su L, Wang Y.

Ageing Res Rev. 2026 Jan;113:102947. doi: 10.1016/j.arr.2025.102947. Epub 2025 Nov 19.

Therapeutic promise of α-hederin in Alzheimer's disease: Insights into inflammation, oxidative stress, and apoptosis modulation

Chettupalli AK, Gupta N, Bukke SPN, Singh MP, Mandal C.

Biomed Pharmacother. 2025 Dec;193:118803. doi: 10.1016/j.biopha.2025.118803. Epub 2025 Nov 22.

Molecular mechanisms of gut microbiota dysbiosis and metabolites in Alzheimer's disease pathogenesis: implications for precision therapeutics

Vaziri Y, Olia JBH, Avci CB, Nourazarian A.

Mol Brain. 2025 Nov 26;18(1):92. doi: 10.1186/s13041-025-01263-1.

Microglia-Mediated Phagocytosis in Alzheimer's Disease: Mechanisms, Heterogeneity, and Therapeutic Insights

Hassan H, Rawlinson C, Lan YL, Jenkins S, Chen R.

Biomolecules. 2025 Nov 20;15(11):1629. doi: 10.3390/biom15111629.

The Role of Bacopa monnieri in Alzheimer's Disease: Mechanisms and Potential Clinical Use-A Review

Wiciński M, Fajkiel-Madajczyk A, Wójcicki J, Ozorowski M, Szambelan M.

Nutrients. 2025 Nov 12;17(22):3538. doi: 10.3390/nu17223538.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias